Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

1228 results about "Drugs synthesis" patented technology

Ongoing production of designer drugs or synthesis drugs like PCP, methamphetamine, MDMA (ecstasy), and bath salts is a dangerous process. Each time a new synthesis drug is made, the ingredients used are made illegal by governing agencies responsible for taking those chemicals off the open market.

IDO restrainer containing (E)-4-(beta-bromo vinyl)benzoyloxy structure

The invention belongs to the technical field of new drug synthesis, and in particular relates to an IDO inhibitor containing (E)-4-(beta-bromovinyl)phenoxy acyl structure, as well as a preparation method thereof. The preparation method comprises the following steps: solvent benzene, (E)-4-(beta-bromovinyl) phenol, carboxylic acid and p-dimethylaminopyridine are added to a flask respectively and magnetically stirred for 5 to 20 minutes at room temperature; then N, N'-dicyclohexylcarbodiimide is added and reacts for 2 to 24 hours at room temperature; after the reaction is completed, the solvent benzene is steamed off after decompression; residue is subjected to column chromatography separation and purification by taking ethyl acetate/petroleum ether as leacheate, and then a needed product can be obtained, wherein the molar ratio of the solvent benzene to the (E)-4-(beta-bromovinyl) phenol is 50-200:1; the molar ratio of the carboxylic acid to the (E)-4-(beta-bromovinyl) phenol is 1-1.5:1; the molar ratio of the p-dimethylaminopyridine to the (E)-4-(beta-bromovinyl) phenol is 0.1-1.5:1; and the molar ratio of the N, N'-dicyclohexylcarbodiimide to the (E)-4-(beta-bromovinyl) phenol is 1-1.2:1. The method takes the (E)-4-(beta-bromovinyl) phenol as a synthesis building block and obtains a series of the novel IDO inhibitors containing the (E)-4-(beta-bromovinyl)phenoxy acyl structure through esterification reaction, and the IDO inhibitors can be used for treating the diseases with the pathological features of IDO mediated tryptophan metabolic pathway.
Owner:SHANGHAI TIANCI BIOLOGICAL VALLEY BIOLOGICAL ENG

Novel synthesis method of mirabegron

The invention provides a novel synthesis method of mirabegron, and belongs to the technical field of drug synthesis. The problems that the yield of synthesized mirabegron is low in the prior art, and the method is unsuitable for large-scale industrial production are solved. The synthesis steps are as follows: 1) performing amino protection, namely reacting 2-aminothiazole-4-acetic acid with an amino protective agent to obtain a mirabegron intermediate product A; 2) performing condensation reaction, namely performing the condensation reaction on the mirabegron intermediate product A and the 4-aminophenethanol to obtain the mirabegron intermediate product B; 3) performing oxidizing reaction, namely performing the oxidizing reaction on the mirabegron intermediate product B and an oxidizing agent to obtain the mirabegron intermediate product C; 4) removing protective agent while performing reductive amination, namely reacting the mirabegron intermediate product C with (R)-2-amino-1-phenethanol under the effect of a reducing agent, and meanwhile removing the protective group on the mirabegron intermediate product C to obtain the mirabegron. The novel synthesis method of mirabegron provided by the invention is low in cost, high in product yield and suitable for large-scale industrial production.
Owner:江苏欣德瑞医药科技有限公司

Process for preparing cefathiamidine

The invention relates to the field of the synthesis of chemical medicaments and discloses a preparation method of cefathiamidine; the method takes chloracetyl chloride as a raw material and comprises the following steps: (1) on the condition of the presence of a solvent, alkali is added so as to cause 7-ACA to be dissolved, and then the chloracetyl chloride is added for a condensation reaction; after the condensation reaction is finished, chloracetyl 7-ACA crystals are separated out with an acid; and (2) on the condition of the presence of both the solvent and a catalyst of a catalyzing amount, the chloracetyl 7-ACA reacts with N, N-di-isopropyl thiourea to produce the cefathiamidine. Besides the advantages of bromoacetyl-bromide preparation method of cefathiamidine, the technology of adopting chloracetyl chloride as the raw material to produce the cefathiamidine also has the advantages that: as no alkali is added into the reaction between the chloracetyl 7-ACA and the N, N-di-isopropyl thiourea, the produced cefathiamidine has lighter color, and better and more stable quality, is more beneficial to store and transport, improves the overall yield, lowers the cost and has broader prospects; and the price of the chloracetyl chloride is one sixth of that of the bromoacetyl bromide, which significantly reduce the cost.
Owner:GUANGZHOU BAIYUNSHAN PHARM CO LTD

Recovery and separation method for solvent containing tetrahydrofuran-carbinol system

The invention relates to an extraction, rectification and separation method and an extraction, rectification and separation process for a solvent containing a tetrahydrofuran-carbinol system which take ethylene glycol as an extractions solvent, and take tetrahydrofuran and carbinol as products. In the drug synthesis process in the pharmaceutical industry, a great quantity of solvents containing the tetrahydrofuran, the carbinol and the like are used, and a mixed liquid waste is generated. Under the normal temperature and normal pressure, the boiling temperatures of the tetrahydrofuran and the carbinol are extremely similar (the boiling temperature of the tetrahydrofuran is 65.4 DEG C and the boiling temperature of the carbinol is 64.8 DEG C), so that the tetrahydrofuran and the carbinol are difficult to separate by adopting a common rectification operation. In addition, the tetrahydrofuran and the carbinol are good in intersolubility and can be well dissolved with great majority of organic or inorganic solvents so as to be incapable of being separated by an extraction operation. According to the method and the process, the waste solvent containing the tetrahydrofuran-carbinol system can be recovered by adopting an extraction and rectification manner, meanwhile, an extracting agent is recycled, so that the obtained tetrahydrofuran and carbinol products are high in purity, impurities are few, the recovered solvent can be recycled in the drug synthesis process, further not only is the cost of pharmacy process reduced, and also the pollution of the waste solvent to the environment is alleviated greatly.
Owner:EAST CHINA UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products